Category: HIV/AIDS
-
STAT+: Merck is urged by patient groups to ensure widespread access to an HIV prevention pill being tested
STAT+: Merck is urged by patient groups to ensure widespread access to an HIV prevention pill being tested In a preemptive move, more than 170 patient advocacy groups from 30 countries are urging Merck to create a global access strategy for an HIV prevention pill, which is still being studied in clinical trials. A key,…
-
Opinion: The U.S. government’s failure to acknowledge World AIDS Day takes us back to a troubling time
Opinion: The U.S. government’s failure to acknowledge World AIDS Day takes us back to a troubling time “Silence = Death.” That was the mantra of determined AIDS activists who quickly concluded the U.S. government was not doing enough to combat the then-emergent AIDS epidemic, which first hit the headlines in 1981. Read the rest… Gavin…
-
STAT+: South Africa is urged by advocates to issue a compulsory license for Gilead’s HIV prevention drug
STAT+: South Africa is urged by advocates to issue a compulsory license for Gilead’s HIV prevention drug Patient advocacy groups have urged the South African government to issue a compulsory license for a groundbreaking HIV prevention treatment after the Trump administration refused to include South Africa in a new program to distribute the drug to…
-
STAT+: DeSantis downplays importance of health insurance as the government shutdown drags on
STAT+: DeSantis downplays importance of health insurance as the government shutdown drags on You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. You might have noticed that the subject line of Tuesday’s newsletter…
-
STAT+: CVS Caremark tells AIDS activists Gilead needs to lower the price of its new HIV drug to get on formularies
STAT+: CVS Caremark tells AIDS activists Gilead needs to lower the price of its new HIV drug to get on formularies For the past three months, CVS Caremark has resisted adding a new Gilead Sciences HIV prevention drug to its formularies, repeatedly explaining there are “clinical, financial, and regulatory considerations” that must be reviewed before…
-
STAT+: Gilead agrees not to raise prices on HIV medicines for state AIDS drug programs
STAT+: Gilead agrees not to raise prices on HIV medicines for state AIDS drug programs After months of tense negotiations, Gilead Sciences has agreed not to boost prices next year for HIV medicines that are sold to state AIDS Drug Assistance Programs, an outcome that lessens the financial strains for agencies that are relied on…
-
STAT+: Gilead wants state AIDS drug programs to pay significant price hikes for HIV meds
STAT+: Gilead wants state AIDS drug programs to pay significant price hikes for HIV meds Gilead Sciences, the largest maker of HIV medicines, is seeking to boost prices significantly for several treatments that are widely distributed by state AIDS Drug Assistance Programs. And the move is adding to financial uncertainty for the programs on top…
-
STAT+: Using mRNA, scientists overcome a key challenge to HIV vaccines
STAT+: Using mRNA, scientists overcome a key challenge to HIV vaccines The decades-long push to develop an HIV vaccine has been riddled with setbacks. But researchers reported on Wednesday that they have managed to circumvent one of the longstanding challenges to developing protective shots against this complex and crafty virus. Scientists used a messenger RNA-based…
-
PEPFAR keeps millions of people with HIV alive and may be spared from Trump spending cuts
PEPFAR keeps millions of people with HIV alive and may be spared from Trump spending cuts The program known as PEPFAR is one of the most effective and popular U.S. foreign aid projects in history, and the government says it has saved the lives of over 25 million people around the world with HIV. But…
-
STAT+: ViiV expands licensing deal for its HIV drug in low-income countries
STAT+: ViiV expands licensing deal for its HIV drug in low-income countries Once again, ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, reflecting ongoing pressure to respond to criticism. Under the latest arrangement, the company is expanding a licensing agreement reached three years ago with…
-
STAT+: Gilead’s CEO on the approval of a powerful new drug to prevent HIV
STAT+: Gilead’s CEO on the approval of a powerful new drug to prevent HIV On Wednesday, the Food and Drug Administration approved a new medicine, lenacapavir (brand name: Yeztugo) that could be the closest thing so far to an HIV vaccine: a long-acting antiviral that, given twice a year, can prevent people from contracting the…